The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis

다국어 초록 (Multilingual Abstract)

Objective: The aim of this study was to assess the SLN detection rate in presumed early stage, low- and intermediate-risk endometrial cancers, the incidence of SLN metastases, and the negative predictive value of SLN mapping performed with indocyanine green (ICG). Methods: A systematic review with meta-analyses was conducted. Study inclusion criteria were A) low- and intermediate-risk endometrial cancer, B) the use of ICG per cervical injection; C) a minimum of twenty included patients per study. To assess the negative predictive value of SLN mapping, D) a subsequent lymphadenectomy was an additional inclusion criterion.
Results: Fourteen studies were selected, involving 2,117 patients. The overall and bilateral SLN detection rates were 95.6% (95% confidence interval [CI]=92.4%–97.9%) and 76.5% (95% CI=68.1%–84.0%), respectively. The incidence of SLN metastases was 9.6% (95% CI=5.1%–15.2%) in patients with grade 1–2 endometrial cancer and 11.8% (95% CI=8.1%–16.1%) in patients with grade 1–3 endometrial cancer. The negative predictive value of SLN mapping was 100% (95% CI=98.8%–100%) in studies that included grade 1–2 endometrial cancer and 99.2% (95% CI=97.9%–99.9%) in studies that also included grade 3. Conclusion: SLN mapping with ICG is feasible with a high detection rate and negative predictive value in low- and intermediate-risk endometrial cancers. Given the incidence of SLN metastases is approximately 10% in those patients, SLN mapping may lead to stage shifting with potential therapeutic consequences. Given the high negative predictive value with SLN mapping, routine lymphadenectomy should be omitted in low- and intermediate- risk endometrial cancer.

참고문헌 (Reference)

1 Rücker G, "Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells" 28 : 721-738, 2009

2 IntHout J, "The Hartung-Knapp-Sidik-Jonkman method for random effects metaanalysis is straightforward and considerably outperforms the standard DerSimonian-Laird method" 14 : 25-, 2014

3 Bogani G, "Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone : long-term results of a propensity-matched analysis" 158 : 77-83, 2020

4 Creasman WT, "Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study" 60 : 2035-2041, 1987

5 Koskas M, "Staging for endometrial cancer : the controversy around lymphadenectomy – Can this be resolved?" 29 : 845-857, 2015

6 Ruscito I, "Sentinel node mapping in cervical and endometrial cancer : indocyanine green versus other conventional dyes-a meta-analysis" 23 : 3749-3756, 2016

7 Holloway RW, "Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis" 141 : 206-210, 2016

8 How JA, "Sentinel lymph node mapping in endometrial cancer : a systematic review and meta-analysis" 70 : 194-214, 2018

9 Abdullah NA, "Sentinel lymph node in endometrial cancer : a systematic review on laparoscopic detection" 2 : 75-78, 2013

10 Taşkın S, "Sentinel lymph node biopsy in early stage endometrial cancer : a Turkish gynecologic oncology group study(TRSGO-SLN-001)" 30 : 299-304, 2020

11 Bodurtha Smith AJ, "Sentinel lymph node assessment in endometrial cancer : a systematic review and meta-analysis" 216 : 459-476, 2017

12 Stephens AJ, "Robotic sentinel lymph node(SLN)mapping in endometrial cancer : SLN symmetry and implications of mapping failure" 30 : 305-310, 2020

13 Morrow CP, "Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium : a Gynecologic Oncology Group study" 40 : 55-65, 1991

14 Whiting PF, "QUADAS-2 : a revised tool for the quality assessment of diagnostic accuracy studies" 155 : 529-536, 2011

15 Backes FJ, "Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue(ISB)and indocyanine green(ICG)in endometrial cancer and the impact of ultrastaging(NCT01818739)" 153 : 496-499, 2019

16 Shah M, "Prognostic significance of hormone receptor(ER/PR)status in endometrial carcinoma in black women : Implications with lymph node metastasis" 38 : e18099-, 2020

17 Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement" 6 : e1000097-, 2009

18 Yang B, "Predicting lymph node metastasis in endometrial cancer using serum CA125 combined with immunohistochemical markers PR and Ki67, and a comparison with other prediction models" 11 : e0155145-, 2016

19 Aarts JW, "Patients’ and gynecologists’ views on sentinel lymph node mapping in low-and intermediate-risk endometrial cancer : a Dutch vignette study" 30 : 813-818, 2020

20 Helgers RJ, "Lymphedema and post-operative complications after sentinel lymph node biopsy versus lymphadenectomy in endometrial carcinomas—A systematic review and meta-analysis" 10 : 120-, 2020

21 Yost KJ, "Lymphedema after surgery for endometrial cancer : prevalence, risk factors, and quality of life" 124 : 307-315, 2014

22 Clinton LK, "Low-volume lymph node metastases in endometrial carcinoma" 27 : 1165-1170, 2017

23 Papadia A, "Laparoscopic indocyanine green sentinel lymph node mapping in endometrial cancer" 23 : 2206-2211, 2016

24 Diniz TP, "Impact of sentinel node mapping in decreasing the risk of lymphocele in endometrial cancer" 28 : 3293-3299, 2021

25 Buda A, "Impact of indocyanine green for sentinel lymph node mapping in early stage endometrial and cervical cancer : comparison with conventional radiotracer 99mTc and/or blue dye" 23 : 2183-2191, 2016

26 Leitao MM Jr, "Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer" 129 : 38-41, 2013

27 Abu-Rustum NR, "IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology : beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers" 30 : 670-683, 2020

28 Ditto A, "Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer : a multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer(MITO)study group" 140 : 1-10, 2020

29 Trovik J, "Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial" 49 : 3431-3441, 2013

30 Federatie Medisch Specialisten, "Guidelines database: endometrial carcinoma guideline" Federatie Medisch Specialisten

31 Xue Y, "Efficacy of sentinel lymph node mapping in endometrial cancer with low-or high-intermediate risk" 125 : 256-263, 2022

32 Concin N, "ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma" 31 : 12-39, 2021

33 Cusimano MC, "Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate-and high-grade endometrial cancer staging" 156 : 157-164, 2021

34 Matei D, "Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer" 380 : 2317-2326, 2019

35 de Boer SM, "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer(PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial" 20 : 1273-1285, 2019

36 Visser NC, "Accuracy of endometrial sampling in endometrial carcinoma : a systematic review and meta-analysis" 130 : 803-813, 2017

37 Ye L, "A prospective study of sentinel lymph node mapping for endometrial cancer : Is it effective in high-risk subtypes?" 24 : e1381-e1387, 2019

38 R-Core-Team, "A language and environment for statistical computing" R Foundation

39 Burg LC, "A cost-effectiveness analysis of three approaches for lymph node assessment in patients with low-and intermediate-risk endometrial cancer" 161 : 251-260, 2021

40 Rossi EC, "A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging(FIRES trial) : a multicentre, prospective, cohort study" 18 : 384-392, 2017